Skip to main content

Table 3 Risk of CRC associated with a 1-SD increase in the circulating sRAGE level

From: Circulating soluble receptor for advanced glycation end products and other factors in type 2 diabetes patients with colorectal cancer

 

OR (95% CI)

P

Model 1

3.331 (2.075–5.347)

<0.001

Model 2

3.603 (2.089–6.217)

<0.001

Model 3

3.609 (2.081–6.257)

<0.001

Model 4

2.289 (1.037–5.051)

0.040

  1. OR odds ratio, CI confidence interval. We assigned the value of 0 to participants without CRC and assigned the value of 1 to those with CRC. Model 1 was adjusted for age, sex, BMI and smoking status. Model 2 was further adjusted for triglyceride, total cholesterol, LDL-c, and HDL-c levels based on model 1. Model 3 was further adjusted for the HOMA-IR score based on model 2. Model 4 was further adjusted for IL-6 levels based on model 3.
Back to article page

BMC Endocrine Disorders

ISSN: 1472-6823

Contact us